Hyaluronic acid butyric esters in cancer therapy

Anti-Cancer Drugs

Volumn 16, Issue 4, 2005, Pages 373-379

  Speranza, Annalisa ^a   Pellizzaro, Cinzia ^a   Coradini, Danila ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Butyrate; Histone deacetylase; Hyaluronic ester

Indexed keywords

BUTYRIC ACID; CELL CYCLE PROTEIN; HISTONE DEACETYLASE INHIBITOR; HYALURONIC ACID; HYALURONIC ACID BUTYL ESTER DERIVATIVE; HYALURONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CANCER GROWTH; CANCER THERAPY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; ESTERIFICATION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; LIVER METASTASIS; LUNG CARCINOMA; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; BUTYRIC ACIDS; ESTERS; HISTONE DEACETYLASES; HUMANS; HYALURONIC ACID; NEOPLASMS;

EID: 15944391746     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200504000-00003     Document Type: Review

References (32)

1. Grunstein M. Histone acetylation and chromatin structure and transcription. Nature 1997; 389:349-352.
2. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Exp 1996; 5:245-254.
3. Marks PA, Rifkind RA, Richon, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev 2001; 1:194-202.
4. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 2001; 13:477-483.
5. Coradini D, Pellizzaro C, Miglierini G, Daidone MG, Perbellini A. Hyaluronic acid as drug delivery for sodium butyrate: improvement of the antiproliferative activity on a breast cancer cell line. Int J Cancer 1999; 81:411-416.
6. Coradini D, Pellizzaro C, Abolafio G, Bosco M, Scarlata I, Stucchi L, et al. Hyaluronic acid butyric esters as promising antineoplastic agents in human lung carcinoma: a preclinical study. Invest New Drugs 2004; 22:207-217.
7. McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993; 34:386-391.
8. Clausen MR. Butyrate and colorectal cancer in animals and in humans. Eur J Cancer Prev 1995; 4:483-490.
9. Tabuchi Y, Arai Y, Kondo T, Takeguchi N, Asano S. Identification of genes responsive to sodium butyrate in colonic epithelial cells. Biochem Biophys Res Commun 2002; 293:1287-1294.
10. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, Daidone MG. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. Cell Prolif 2000; 33:139-146.
11. Pellizzaro C, Coradini D, Abolafio G, Daidone MG. Modulation of cell cycle-related proteins but not of p53 expression by sodium butyrate in a human non-small cell lung cancer cell line. Int J Cancer 2001; 91:658-664.
12. Medina V, Edmonds B, Young GP, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997; 57:3697-3707.
13. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23:1283-1287.
14. Pouillart P, Cerutti I, Ronco G, Villa P, Chany C. Butyric monosaccharide ester-induced cell differentiation and anti-tumor activity in mice. Importance of their prolonged biological effect for clinical application in cancer therapy. Int J Cancer 1991; 49:89-95.
15. Planchon P, Pouillart P, Ronco G, Cerutti I, Villa P, Pieri F. Differential elimination of synthetic butyric triglycerides in vivo: a pharmacokinetic study. J Pharm Sci 1993; 82:1046-1048.
16. Aviram A, Zimrah Y, Shaklai M, Nudelman A, Rephaeli A. Comparison between the effect of butyric acid and its pro-drug pivaloyloxy-methylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line. Int J Cancer 1994; 56:906-909.
17. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177:443-455.
18. Günthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
19. Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, et al. Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res 2004; 10:4822-4830.
20. Simeister G, Martiny-Baron G, Marmé D. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities. Cancer Metast Rev 1998; 17:241-248.
21. Pellizzaro C, Coradini D, Daidone MG. Modulation of angiogenesis-related proteins synthesis by sodium butyrate in colon cancer cell line HT29. Carcinogenesis 2002; 23:735-740.
22. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid (SAHA) administered intravenously. Clin Cancer Res 2003; 9:3578-3588.
23. Sandor V, Bakke S, Robey RW, Kang MH, Blagoslonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor depsipeptide (FR901228, NSC630176) in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-728.
24. Gojo I, Karp JE, Mann D. Phase I study of histone deacetylase inhibitor (HDI) MS-275 in adults with refractory or relapsed haematologic malignancies. Proc Am Soc Hematol 2002; abstr 2198.
25. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 1999; 94:1401-1408.
26. Jones PA, Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293:1068-1070.
27. Zhu W-G, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61:1327-1333.
28. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:597-601.
29. Banerjee P, Chatterjee M. Antiproliferative role of vitamine D and its analogs - a brief overview. Mol Cell Biochem 2003; 253:247-254.
30. Degos L, Dombret H, Chomienne C, Daniel MT, Miclea JM, Chastang C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood 1995; 85:2643-2653.
31. Gaschott T, Stein J. Short-chain fatty acids and colon cancer cells: the vitamin D receptor-butyrate connection. Rec Results Cancer Res 2003; 164:247-257.
32. Warrell Jr RP, HE LZ, Richon V, Calleja E, Pandolfi PP. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998; 90:1621-1625.